Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)

Investigational New Drugs

Volumn 31, Issue 4, 2013, Pages 1023-1034

  Erba, Harry P ^a,g   Sayar, Hamid ^b   Juckett, Mark ^c   Lahn, Michael ^d   Andre, Valerie ^d   Callies, Sophie ^d   Schmidt, Shelly ^d   Kadam, Sunil ^d   Brandt, John T ^d   Van Bockstaele, Dirk ^e   Andreeff, Michael ^f  

^a UNIVERSITY OF MICHIGAN   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e LabCorp Clinical Trials   (Belgium)

^f UNIVERSITY OF TEXAS   (United States)

^g Division of Hematology/Oncology   (United States)

Author keywords

Acute myeloid leukemia; Antisense; Cytarabine; Idarubicin

Indexed keywords

CYTARABINE; GATAPARSEN; IDARUBICIN; SURVIVIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOODSTREAM INFECTION; BRAIN HEMORRHAGE; BRAIN HYPOXIA; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLOSTRIDIUM INFECTION; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; INSOMNIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; SEPSIS; TUMOR LYSIS SYNDROME; UPREGULATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DEMOGRAPHY; FEMALE; HUMANS; IDARUBICIN; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RECURRENCE; TREATMENT OUTCOME;

EID: 84880923165     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9935-x     Document Type: Article

References (30)

1. Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliand DG, Griffin JD (2005) Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105:54-60. doi: 10.1182/blood-2004-03-0891
2. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937-951. doi: 10.1182/blood-2009-03-209262
3. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, Habdank M, Spath D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Dohner H, German-Austrian Acute Myeloid Leukemia Study Group (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909-1918. doi: 10.1056/NEJMoa074306
4. Tallman MS (2005) New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematology Am Soc Hematol Educ Program 143-150. doi: 10.1182/asheducation-2005.1.143
5. Cong XL, Han ZC (2004) Survivin and leukemia. Int J Hematol 80:232-238. doi: 10.1532/IJH97.A10408
6. Liu K, He X, Lei XZ, Zhao LS, Tang H, Liu L, Lei BJ (2003) Pathomorphological study on location and distribution of Kupffer cells in hepatocellular carcinoma. World J Gastroenterol 9:1946-1949
7. Carter BZ, Milella M, Altieri DC, Andreeff M (2001) Cytokine-regulated expression of survivin in myeloid leukemia. Blood 97:2784-2790. doi: 10.1182/blood.V97.9.2784
8. Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, Rousselot P, Sigaux F, Degos L, Altieri DC, Dombret H (2000) Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 111:196-203. doi: 10.1111/j.1365-2141.2000.02328.x
9. Hernandez-Boluda JC, Bellosillo B, Vela MC, Colomer D, Alvarez-Larran A, Cervantes F (2005) Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients. Leuk Lymphoma 46:717-722. doi: 10.1080/10428190500052131
10. Carter BZ, Wang RY, Schober WD, Milella M, Chism D, Andreeff M (2003) Targeting survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells. Cell Cycle 2:488-493. doi: 10.4161/cc.2.5.500
11. Carrasco RA, Stamm NB, Marcusson E, Sandusky G, Iversen P, Patel BK (2011) Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther 10:221-232. doi: 10.1158/1535-7163.MCT-10-0756
12. Talbot DC, Ranson M, Davies J, Lahn M, Callies S, André V, Kadam S, Burgess M, Slapak C, Olsen AL, McHugh PJ, de Bono JS, Matthews J, Saleem A, Price P (2010) Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res 16:6150-6158. doi: 10.1158/1078-0432.CCR-10-1932
13. Wacheck V, Lahn M, Dickinson G, Füreder W, Meyer R, Herndlhofer S, Füreder T, Dorfner G, Pillay S, André V, Burkholder TP, Akunda JK, Flye-Blakemore L, Van Bockstaele D, Schlenk RF, Sperr WR, Valent P (2011) Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics. Cancer Manag Res 3:157-175. doi: 10.2147/CMAR.S19341
14. Yang W, Maqsodi B, Ma Y, Bui S, Crawford KL, McMaster GK, Witney F, Luo Y (2006) Direct quantification of gene expression in homogenates of formalin-fixed, paraffin-embedded tissues. Biotechniques 40:481-486. doi: 10.2144/000112133
15. Callies S, André V, Patel B, Waters D, Francis P, Burgess M, Lahn M (2011) Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide. Br J Clin Pharmacol 71:416-428. doi: 10.1111/j.1365-2125.2010.03836.x
16. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, LoCocco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD (2003) Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649. doi: 10.1200/JCO.2003.04.036
17. Shults K, Flye L, Green L, Daly T, Manro JR, Lahn M (2009) Patient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patterns. Cancer Manag Res 1:49-59. doi: 10.2147/CMAR.S5611
18. Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M (2009) Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 27:4741-4746. doi: 10.1200/JCO.2009.21.8172
19. Saleem A, Matthews JC, Ranson M, Callies S, Andre V, Lahn M, Dickinson C, Prenant C, Brown G, McMahon A, Talbot DC, Jones T, Price PM (2011) Molecular imaging and pharmacokinetic analysis of carbon-11 labeled antisense oligonucleotide LY2181308 in cancer patients. Theranostics 1:290-301. doi: 10.7150/thno/v01p0290
20. Dean E, Jodrell D, Connolly K, Danson S, Jolivet J, Durkin J, Morris S, Jowle D, Ward T, Cummings J, Dickinson G, Aarons L, Lacasse E, Robson L, Dive C, Ranson M (2009) Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol 27:1660-1666. doi: 10.1200/JCO.2008.19.5677
21. Altieri DC (2010) Survivin and IAP proteins in cell death mechanisms. Biochem J 430:199-205. doi: 10.1042/BJ20100814
22. Arora V, Cheung HH, Plenchette S, Micali OC, Liston P, Korneluk RG (2007) Degradation of survivin by the XIAP-XAF1 complex. J Biol Chem 282:26202-26209. doi: 10.1074/jbc.M700776200
23. Wang H, Holloway MP, Ma L, Cooper ZA, Riolo M, Samkari A, Elenitoba-Johnson KS, Chin YE, Altura RA (2010) Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J Biol Chem 285:36129-36137. doi: 10.1074/jbc.M110.152777
24. Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ (2011) Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 117:5701-5709. doi: 10.1182/blood-2010-04-280123
25. Crooke S (2008) Antisense drug technology: Principles, strategies, and application. CRC Press (Taylor&Francis Group), 2nd edition, Boca Raton, FL
26. Flanagan JM, Funes JM, Henderson S, Wild L, Carey N, Boshoff C (2009) Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets. Mol Cancer Ther 8:249-260. doi: 10.1158/1535-7163.MCT-08-0636
27. Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL, Konopleva M, Kantarjian H, Andreeff M (2011) XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34 + 38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis 16:67-74. doi: 10.1007/s10495-010-0545-1
28. Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE, Morris JC (2011) Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer 10:35. doi: 10.1186/1476-4598-10-35
29. Bhattacharyya J, Mihara K, Ohtsubo M, Yasunaga S, Takei Y, Yanagihara K, Sakai A, Hoshi M, Takihara Y, Kimura A (2012) Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression. Cancer Sci 103:34-41. doi: 10.1111/j.1349-7006.2011.02121.x
30. Guo L, Tang M, Yang L, Xiao L, Bode AM, Li L, Dong Z, Cao Y (2012) Epstein-Barr virus oncoprotein LMP1 mediates survivin upregulation by p53 contributing to G1/S cell cycle progression in nasopharyngeal carcinoma. Int J Mol Med 29:574-580. doi: 10.3892/ijmm.2012.889